相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma
Cara Haymaker et al.
CANCER DISCOVERY (2021)
ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti -PD-1 therapy.
Marcus O. Butler et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A phase 2 study to evaluate the safety and efficacy of Intratumoral (IT) injection of the TLR9 agonist IMO-2125 (IMO) in combination with ipilimumab (ipi) in PD-1 inhibitor refractory melanoma
Adi Diab et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma
Matthew J. Frank et al.
CANCER DISCOVERY (2018)
Modulation of checkpoint expression in tumor microenvironment by intratumoral administration of a novel TLR9 agonist: Rationale for combination therapy
Wayne Jiang et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Intratumoral Immunization: A New Paradigm for Cancer Therapy
Aurelien Marabelle et al.
CLINICAL CANCER RESEARCH (2014)
Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non-Small-Cell Lung Cancer
Vera Hirsh et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Taro Kawai et al.
NATURE IMMUNOLOGY (2010)
Impact of Secondary Structure of Toll-Like Receptor 9 Agonists on Interferon Alpha Induction
Dong Yu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Toll-like receptors in innate immunity
K Takeda et al.
INTERNATIONAL IMMUNOLOGY (2005)
分享论文
